Oncogenic role of transcriptional coactivators TAZ (WWTR1) and VGLL1 in aggressive subtypes of breast, endometrial, and ovarian cancer. (Q3154482): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): AZ (coded by WWTR1) is a transcriptional coactivator that acts as the final effector of the Hippo tumor suppressor pathway. VGLL1 (vestigial-like 1) also encodes a transcriptional coactivator, of unknown function in humans, which interacts, like TAZ, with members of the TEAD transcription factor family. mir-934 is a miRNA of unknown function that is located in the intronic sequence of VGLL1. Preliminary studies of our group suggest that these th...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Oncogenic role of transcriptional coactivators TAZ (WWTR1) and VGLL1 in aggressive subtypes of breast, endometrial, and ovarian cancer. | |||
Revision as of 15:39, 12 October 2021
Project Q3154482 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Oncogenic role of transcriptional coactivators TAZ (WWTR1) and VGLL1 in aggressive subtypes of breast, endometrial, and ovarian cancer. |
Project Q3154482 in Spain |
Statements
112,625.0 Euro
0 references
225,250.0 Euro
0 references
50.0 percent
0 references
1 January 2014
0 references
31 March 2018
0 references
FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
AZ (codificada por WWTR1) es un coactivador transcripcional que actúa como efector final de la vía supresora de tumores Hippo. VGLL1 (vestigial-like 1) codifica también un coactivador transcripcional, de función desconocida en humanos, que interacciona, al igual que TAZ, con miembros de la familia de factores de transcripción TEAD. mir-934 es un miRNA de función desconocida que esta localizado en la secuencia intrónica de VGLL1. Estudios preliminares de nuestro grupo sugieren que estos tres factores se sobreexpresan en carcinomas de mama, endometrio y ovario de tipos histológicos agresivos. El presente proyecto traslacional pretende analizar la expresión de TAZ y VGLL1 mediante inmunohistoquímica en series clínicas de cáncer de mama, endometrio y ovario, y determinar asociaciones con características clínico-patológicas. Determinaremos si los niveles de expresión de TAZ y VGLL1 en estas neoplasias se modulan mediante amplificación de los respectivos loci, y/o metilación del promotor, mediante estudios de hibridación in situ fluorescente y la plataforma Sequenom MassArray® MALDI-TOF, respectivamente. Asimismo, pretendemos estudiar in vitro el papel oncogénico de TAZ en cáncer de endometrio y ovario, y el papel oncogénico de Vgll1 en cáncer de mama, mediante ensayos de pérdida y ganancia de función analizando los cambios que se induzcan en la morfología, proliferación, migración y perfil transcripcional. Finalmente, este proyecto tiene por objetivo analizar el papel de miR-934 en la regulación de la expresión del gen del receptor de estrógenos (ESR1) y en el fenotipo tumoral. (Spanish)
0 references
AZ (coded by WWTR1) is a transcriptional coactivator that acts as the final effector of the Hippo tumor suppressor pathway. VGLL1 (vestigial-like 1) also encodes a transcriptional coactivator, of unknown function in humans, which interacts, like TAZ, with members of the TEAD transcription factor family. mir-934 is a miRNA of unknown function that is located in the intronic sequence of VGLL1. Preliminary studies of our group suggest that these three factors are overexpressed in carcinomas of the breast, endometrium, and ovary of aggressive histological types. This translational project aims to analyse the expression of TAZ and VGLL1 by immunohistochemistry in clinical series of breast, endometrial and ovarian cancer, and to determine associations with clinical and pathological characteristics. We will determine whether the expression levels of TAZ and VGLL1 in these neoplasms are modulated by amplification of the respective loci, or methylation of the promoter, using fluorescent in situ hybridisation studies and the Sequenom MassARRAY® MALDI-TOF platform, respectively. In addition, we intend to study in vitro the oncogenic role of TAZ in endometrial and ovarian cancer, and the oncogenic role of Vgll1 in breast cancer, through function loss and gain trials by analysing changes that are induced in morphology, proliferation, migration and transcriptional profile. Finally, this project aims to analyse the role of miR-934 in regulating the expression of the estrogen receptor gene (ESR1) and in the tumor phenotype. (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI13_02477
0 references